The genotyping supports a study known as the Cancer Genetic Markers of Susceptibility (CGEMS), a National Cancer Institute (NCI) strategic initiative.
The CGEMS initiative is designed to map susceptibility in prostrate and breast cancers, with the aim of understanding disease cause and progression, and then identifying strategies for prevention, earlier detection and treatment.
Illumina will use its Sentrix HumanHap300, BeadChip and Infinium assay to perform the genotyping. Each HumanHap300 BeadChip can query over 317,000 SNP markers composed principally of “tagSNPs” identified and validated by the international HapMap project.
Post-genotyping data analysis will be conducted under the guidance of NCI’s advanced technology center core genotyping facility.
“We’re very pleased to extend our relationship with the NCI,” said Jay Flatley, Illumina president and CEO. “We’re looking forward to engaging the capabilities of our world-class services organization to support the CGEMS initiative.”